Microvast Holdings announces departure of chief financial officer
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), recently sold shares of the company’s common stock. The medical device company, currently valued at approximately $754 million, has shown strong momentum with a nearly 29% price return over the past six months. According to InvestingPro data, the stock maintains a "GREAT" financial health score. According to a Form 4 filing with the Securities and Exchange Commission, Dunn sold 337 shares at an average price of $16.5056 per share, totaling $5,562. This transaction was executed to cover tax withholding obligations related to the vesting of restricted stock units, as noted in the filing. Following this sale, Dunn directly owns 17,290 shares and indirectly holds 109,134 shares through The Jeffrey W. Dunn Living Trust. With analyst price targets ranging from $15 to $32, and a strong consensus recommendation of 1.44 (where 1 is Strong Buy), InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about SI-BONE’s financial outlook.
In other recent news, SI-BONE Inc. reported a significant 19% increase in worldwide revenue, reaching $40.3 million for the third quarter of 2024. This growth was primarily driven by an 18% rise in U.S. sales and a 21% increase in international sales. The company also achieved a gross profit of $31.9 million, with a gross margin of 79%. Piper Sandler analysts anticipate positive fiscal year outlooks for several healthcare companies, including SI-BONE. They expect potential upside for SI-BONE’s consensus numbers, which typically issue full-year guidance with Q4 earnings. Needham, another financial services firm, reiterated its Buy rating on SI-BONE, highlighting the company’s robust financial position. These are some of the recent developments that investors might find noteworthy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.